Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Adicet Bio ( (ACET) ) is now available.
Adicet Bio, Inc. has launched a Phase 1 clinical trial for ADI-270, targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors. The company also began dosing a lupus nephritis patient in a trial for ADI-001, highlighting its focus on autoimmune diseases. Preliminary data for ADI-270 is expected by mid-2025, promising advancements in cancer treatment.
For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.